TP53 and neoplasm: Considering some patient clusters with tumor relapses that additionally acquire p53 and RAS mutations, as well as mechanisms activating telomerase or the ALT, it may be beneficial that the targeted drugs are offered as first-line therapy to avoid inducing untreatable genetic chaos in tumors.